Generali Investments Management Co LLC Purchases 18,566 Shares of Boston Scientific Corporation $BSX

Generali Investments Management Co LLC raised its position in Boston Scientific Corporation (NYSE:BSX) by 63.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 48,040 shares of the medical equipment provider’s stock after acquiring an additional 18,566 shares during the quarter. Generali Investments Management Co LLC’s holdings in Boston Scientific were worth $2,050,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. increased its stake in shares of Boston Scientific by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock worth $13,319,060,000 after purchasing an additional 1,436,550 shares during the last quarter. State Street Corp lifted its stake in Boston Scientific by 1.4% in the 4th quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock valued at $6,278,422,000 after purchasing an additional 920,495 shares during the last quarter. Capital World Investors grew its holdings in Boston Scientific by 1.9% during the fourth quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock worth $2,588,953,000 after purchasing an additional 502,627 shares during the period. Norges Bank acquired a new position in Boston Scientific during the fourth quarter worth approximately $2,199,395,000. Finally, Morgan Stanley raised its stake in Boston Scientific by 10.8% in the fourth quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock valued at $2,189,289,000 after buying an additional 2,246,308 shares during the period. Institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling

In other news, Director David C. Habiger acquired 2,250 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The stock was acquired at an average price of $55.92 per share, with a total value of $125,820.00. Following the completion of the transaction, the director directly owned 13,878 shares of the company’s stock, valued at $776,057.76. This trade represents a 19.35% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Cheryl Pegus acquired 1,770 shares of Boston Scientific stock in a transaction on Wednesday, May 20th. The shares were purchased at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the purchase, the director directly owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 204,322 shares of company stock worth $9,939,221 in the last ninety days. 0.34% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on BSX shares. Royal Bank Of Canada cut their price objective on Boston Scientific from $85.00 to $70.00 and set an “outperform” rating for the company in a research report on Thursday, July 30th. BTIG Research dropped their price target on Boston Scientific from $65.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, July 29th. Stifel Nicolaus set a $60.00 price target on Boston Scientific in a report on Wednesday, July 29th. Argus reaffirmed a “hold” rating on shares of Boston Scientific in a research report on Friday, July 31st. Finally, Piper Sandler reiterated an “overweight” rating and issued a $65.00 price objective on shares of Boston Scientific in a report on Friday, June 12th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $71.62.

Boston Scientific Price Performance

Boston Scientific stock opened at $50.42 on Tuesday. The stock’s fifty day moving average price is $45.80 and its two-hundred day moving average price is $60.25. Boston Scientific Corporation has a one year low of $42.20 and a one year high of $109.50. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The firm has a market cap of $73.07 billion, a PE ratio of 20.41, a price-to-earnings-growth ratio of 1.08 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company’s revenue was up 7.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, research analysts expect that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific declared that its Board of Directors has initiated a share repurchase plan on Monday, May 18th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s board of directors believes its stock is undervalued.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.